Drug Profile


Alternative Names: APT 070; APT 070C

Latest Information Update: 30 Apr 2015

Price : $50

At a glance

  • Originator Adprotech
  • Developer Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Recombinant proteins
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Reperfusion injury
  • Discontinued Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis; Shock; Transplant rejection

Most Recent Events

  • 12 Feb 2015 Phase-III clinical trials in Reperfusion injury in United Kingdom (unspecified route)
  • 12 Mar 2014 Discontinued - Phase-I for Shock in Canada (unspecified route) prior to 2014
  • 12 Mar 2014 Discontinued - Phase-II for Transplant rejection in United Kingdom (unspecified route) prior to 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top